Respiratory Antiviral Treatment Market (By Disease Type: Pneumonia, Influenza, Bronchiolitis, Upper Respiratory Tract Infection, Others; By Drug Class: Nucleoside Analogs, Neuraminidase Inhibitors, Ion Channel Blockers, Fusion Protein Inhibitors; By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Respiratory Antiviral Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Respiratory Antiviral Treatment Market, by Disease Type, 2024-2033
8.1.1 Pneumonia
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Influenza
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Bronchiolitis
8.1.3.1. Market Revenue and Forecast (2021-2033)
8.1.4. Upper Respiratory Tract Infection
8.1.4.1. Market Revenue and Forecast (2021-2033)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2021-2033)
9.1. Respiratory Antiviral Treatment Market, by Drug Class, 2024-2033
9.1.1. Nucleoside Analogs
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Neuraminidase Inhibitors
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Ion Channel Blockers
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Fusion Protein Inhibitors
9.1.4.1. Market Revenue and Forecast (2021-2033)
10.1. Respiratory Antiviral Treatment Market, by Distribution Channel, 2024-2033
10.1.1. Hospital Pharmacy
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Retail Pharmacy
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Online Pharmacy
10.1.3.1. Market Revenue and Forecast (2021-2033)
11.1. North America
11.1.1. Market Revenue and Forecast, by Disease Type (2021-2033)
11.1.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.1.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Disease Type (2021-2033)
11.1.4.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Disease Type (2021-2033)
11.1.5.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Disease Type (2021-2033)
11.2.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.2.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Disease Type (2021-2033)
11.2.4.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Disease Type (2021-2033)
11.2.5.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Disease Type (2021-2033)
11.2.6.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Disease Type (2021-2033)
11.2.7.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Disease Type (2021-2033)
11.3.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.3.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Disease Type (2021-2033)
11.3.4.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Disease Type (2021-2033)
11.3.5.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Disease Type (2021-2033)
11.3.6.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Disease Type (2021-2033)
11.3.7.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Disease Type (2021-2033)
11.4.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Disease Type (2021-2033)
11.4.4.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Disease Type (2021-2033)
11.4.5.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Disease Type (2021-2033)
11.4.6.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Disease Type (2021-2033)
11.4.7.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Disease Type (2021-2033)
11.5.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Disease Type (2021-2033)
11.5.4.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Disease Type (2021-2033)
11.5.5.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
12.1. F. Hoffmann-La Roche Ltd.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Mylan N.V.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Sanofi
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Pfizer Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. GlaxoSmithKline plc
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Novartis AG
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Merck & Co., Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Dr. Reddy's Laboratories Ltd.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Zydus Cadila
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Johnson & Johnson Private Limited
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample